23 May Acquisition of Gulf Inject LLC Completed by GlobalOne Healthcare
GlobalOne Healthcare Holding LLC (GHH) has completed the acquisition of Gulf Inject LLC (GI) from Ras Al Khaimah-based Gulf Pharmaceutical Industries (Julphar), a listed UAE-based pharmaceutical company. The 100% acquisition, which includes Gulf Inject’s Jebel Ali Free Zone branch, enhances GHH’s healthcare investment portfolio.
GHH’s healthcare portfolio includes biopharma, manufacturing, medical supply chain, hospital and clinic management, healthcare technology, and occupational health and wellness.
The acquisition aligns with the UAE’s recent recognition as having the most competitive industrial sector in the Arab world, climbing five places to 30th in the 2021 United Nations’ Industrial Organisation’s (UNIDO) Competitive Industrial Performance Index (CIP) report. This progress supports the UAE’s industrial strategy, Operation 300bn, aimed at advancing the national industrial sector to stimulate economic growth.
Commenting on the acquisition, Murshed Al Redaini, Group Chief Executive Officer, stated, “We are pleased to welcome Gulf Inject to our portfolio. Their production facilities add significant strategic value to our expanding healthcare manufacturing and distribution ecosystem, advancing our mission to improve health outcomes and patient quality of life.”
Founded in 1994, Gulf Inject manufactures and distributes sterile parenteral solutions and is a key player in fluid management therapy in the UAE. From its well-established production facility in JAFZA Dubai, GI manufactures 65 products, including injectables, IV infusions, antibiotics, local anaesthetics, and hypertonic solutions used in treating critical and chronically ill patients.
Suresh Vaidhyanathan, Group CFO, noted, “The acquisition will generate several synergies that collectively position GHH as a premier healthcare investment company in the region, reinforcing our commitment to supporting UAE’s strategic objectives in local manufacturing.”
Ashraf Radwan, CEO of GlobalOne Healthcare, explained that “in combination with GHH’s Wellpharma Medical Solutions (WMS), this acquisition will allow GHH to assume a market-leading position in domestic IV fluid provision, placing us among the top three regional players in the Middle East. Together, Gulf Inject and WMS will exceed 28 million units of general intravenous fluids, electrolytes, and injectable antibiotics, with an additional 20 million units of small volume sterile formulations and 1.2 million units of large volume formulations, including dialysis solutions.”
He added, “Gulf Inject’s solutions will also be complemented by our existing range of therapeutic injectables and eye care products.”